Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03593239




Registration number
NCT03593239
Ethics application status
Date submitted
1/06/2018
Date registered
20/07/2018
Date last updated
21/06/2021

Titles & IDs
Public title
Comparing the Pharmacokinetics of Nicotine Salt Based ENDS in Healthy Smokers
Scientific title
A Ten Sequence, Open Label, Randomized Crossover Study Comparing Nicotine Pharmacokinetics of JUUL 1.7% and JUUL 5% Nicotine Salt Based Electronic Nicotine Delivery System (ENDS Products), in Healthy Adult Smokers
Secondary ID [1] 0 0
PROT-00008 / v2.1
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Nicotine Dependence 0 0
Nicotine Dependence, Cigarettes 0 0
Tobacco Use 0 0
Tobacco Smoking 0 0
Condition category
Condition code
Mental Health 0 0 0 0
Addiction
Mental Health 0 0 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - Tobacco flavored JUUL 1.7% ENDS
Other interventions - Tobacco flavored JUUL 5% ENDS
Other interventions - Mint flavored JUUL 1.7% ENDS
Other interventions - Mint flavored JUUL 5% ENDS
Other interventions - Fruit Medley flavored JUUL 1.7% ENDS
Other interventions - Fruit Medley flavored JUUL 5% ENDS
Other interventions - Crème brulee flavored JUUL 1.7% ENDS
Other interventions - Crème brulee flavored JUUL 5% ENDS
Other interventions - JUUL 1.7% ENDS 10 puffs vs. ad lib puffs
Other interventions - JUUL 5% ENDS 10 puffs vs. ad lib puffs

Experimental: Tobacco flavored JUUL 1.7% ENDS - Tobacco flavored JUUL 1.7% ENDS (10 puffs)

Experimental: Tobacco flavored JUUL 5% ENDS - Tobacco flavored JUUL 5% ENDS (10 puffs)

Experimental: Mint flavored JUUL 1.7% ENDS - Mint flavored JUUL 1.7% ENDS (10 puffs);

Experimental: Mint flavored JUUL 5% ENDS - Mint flavored JUUL 5% ENDS (10 puffs)

Experimental: Fruit Medley flavored JUUL 1.7% ENDS - Fruit Medley flavored JUUL 1.7% ENDS (10 puffs)

Experimental: Fruit Medley flavored JUUL 5% ENDS - Fruit Medley flavored JUUL 5% ENDS (10 puffs)

Experimental: Crème brulee flavored JUUL 1.7% ENDS - Crème brulee flavored JUUL 1.7% ENDS (10 puffs)

Experimental: Crème brulee flavored JUUL 5% ENDS - Crème brulee flavored JUUL 5% ENDS (10 puffs)

Experimental: JUUL 1.7% ENDS 10 puffs vs. ad lib puffs - Tobacco flavoured JUUL 1.7% ENDS products 10 puffs versus ad libitum puffs

Experimental: JUUL 5% ENDS 10 puffs vs. ad lib puffs - Tobacco flavoured JUUL 5% ENDS products 10 puffs versus ad libitum puffs


Other interventions: Tobacco flavored JUUL 1.7% ENDS
Treatment with Tobacco flavored JUUL 1.7% ENDS (10 puffs)

Other interventions: Tobacco flavored JUUL 5% ENDS
Treatment with Tobacco flavored JUUL 5% ENDS(10 puffs)

Other interventions: Mint flavored JUUL 1.7% ENDS
Treatment with Mint flavored JUUL 1.7% ENDS(10 puffs)

Other interventions: Mint flavored JUUL 5% ENDS
Treatment with Mint flavored JUUL 5% ENDS(10 puffs)

Other interventions: Fruit Medley flavored JUUL 1.7% ENDS
Treatment with Fruit Medley flavored JUUL 1.7% ENDS(10 puffs)

Other interventions: Fruit Medley flavored JUUL 5% ENDS
Treatment with Fruit Medley flavored JUUL 5% ENDS(10 puffs)

Other interventions: Crème brulee flavored JUUL 1.7% ENDS
Treatment with Crème brulee flavored JUUL 1.7% ENDS(10 puffs)

Other interventions: Crème brulee flavored JUUL 5% ENDS
Treatment with Crème brulee flavored JUUL 5% ENDS(10 puffs)

Other interventions: JUUL 1.7% ENDS 10 puffs vs. ad lib puffs
Treatment with JUUL 1.7% ENDS 10 puffs vs. ad libitum puffs

Other interventions: JUUL 5% ENDS 10 puffs vs. ad lib puffs
Treatment with JUUL 5% ENDS 10 puffs vs. ad libitum puffs
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Compare nicotine pharmacokinetics(PK) in smokers and e-cigarette users measuring Time to Maximum Concentration(Tmax)
Timepoint [1] 0 0
38 Days
Primary outcome [2] 0 0
Compare nicotine pharmacokinetics(PK) in smokers and e-cigarette users measuring Concentration Maximum (Cmax)
Timepoint [2] 0 0
38 Days
Primary outcome [3] 0 0
Compare nicotine pharmacokinetics(PK) in smokers and e-cigarette users measuring Cmax-baseline and Area Under the Curve ( AUC) 1hour
Timepoint [3] 0 0
38 Days
Primary outcome [4] 0 0
Compare nicotine pharmacokinetics(PK) in smokers and e-cigarette users measuring AUC1hour-baseline of nicotine
Timepoint [4] 0 0
38 Days
Secondary outcome [1] 0 0
Change in Pre and Post exhaled carbon monoxide (CO) values for each subject and Test Product.
Timepoint [1] 0 0
38 Days
Secondary outcome [2] 0 0
To compare user satisfaction measures of each Test Product when consumed by smokers and e-cigarette users.
Timepoint [2] 0 0
38 Days

Eligibility
Key inclusion criteria
* Male or female aged 18 to 60 years of age inclusive.
* Current smoker or e-cigarette user:
* Able to participate, and willing to give written informed consent and to comply with the ° study restrictions.
Minimum age
18 Years
Maximum age
60 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Exclusion criteria:

* Clinically significant abnormality on screening ECG.
* Sustained blood pressure recordings at screening of < 90 mmHg or > 150 mmHg for systolic blood pressure, or < 50 mmHg or > 90 mmHg for diastolic blood pressure.
* Sustained resting heart rate of > 100 or < 40 beats per minute at screening.
* Positive result for urine drugs of abuse test or alcohol breath test at screening.
* Clinically significant abnormality in laboratory test results at screening, in the opinion of the Investigator.
* Positive urine pregnancy test at screening or Assessment Days in female subjects of child bearing potential.
* Any clinically significant concomitant disease or conditions.

Study design
Purpose of the study
Other
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not applicable
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/06/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
26/07/2018
Sample size
Target
Accrual to date
Final
24
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Juul Labs, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A Ten Sequence, Open Label, Randomized Crossover Study Comparing Nicotine Pharmacokinetics of JUUL 1.7% and JUUL 5% Nicotine Salt Based ENDS Products, in Healthy Adult Smokers.
Trial website
https://clinicaltrials.gov/study/NCT03593239
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Christopher Wynne, MD
Address 0 0
Christchurch Clinical Studies Trust Ltd
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03593239